<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04025437</url>
  </required_header>
  <id_info>
    <org_study_id>RT-HCC-PVTT</org_study_id>
    <nct_id>NCT04025437</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Radiotherapy for HCC Involving Type I PVTT</brief_title>
  <official_title>Neoadjuvant Radiotherapy for Patients With Hepatocellular Carcinoma Involving Type I Portal Vein Tumor Thrombus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangxi Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rate of patients with hepatocellular carcinoma (HCC) involving portal vein tumor thrombus
      (PVTT) is up to 50% in Guangxi province, China. Some of them will receive hepatic resection,
      especially those with type I or II PVTT. However, 5-years recurrence rate is up to 75% after
      surgery. Some retrospective studies found postoperative radiotherapy may reduce the rate of
      recurrence. Moreover, few retrospective studies also found neoadjuvant radiotherapy (PMID:
      27317960) may improve overall survival for HCC patients involving type II/III PVTT. However,
      the safety and efficacy of neoadjuvant raidotherapy for HCC involving type I PVTT is unknown.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Neoadjuvant Radiotherapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>From the date of hepatectomy or neoadjuvant radiotherapy to death or the end of follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free survival</measure>
    <time_frame>1 year</time_frame>
    <description>From the date of hepatectomy to HCC recurrence or the end of follow-up.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">214</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Hepatectomy alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will receive hepatectomy alone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant radiotherapy plus hepatectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiotherapy for type I PVTT will be perfomed before hepatectomy. Hepatic resection will be performed in about 4 weeks after radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hepatectomy alone</intervention_name>
    <description>Patients in this group will receive hepatectomy alone.</description>
    <arm_group_label>Hepatectomy alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Neoadjuvant radiotherapy</intervention_name>
    <description>Radiotherapy for type I PVTT will be perfomed before hepatectomy. Hepatic resection will be performed in about 4 weeks after radiotherapy.</description>
    <arm_group_label>Neoadjuvant radiotherapy plus hepatectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-75 years;

          -  Patients with resectable primary hepatocellular carcinoma and Cheng's type I portal
             vein tumor thrombus;

          -  Child-Pugh A or B (7 score) liver function;

          -  With more than 3 months expected survival;

          -  The volume of residual liver more than 30%;

          -  Patients agree to take part in.

        Exclusion Criteria:

          -  Patients with primary hepatocellular carcinoma and Cheng's type II/III/IV portal vein
             tumor thrombus

          -  Previous history of epigastric radiotherapy

          -  With extrahepatic metastasis

          -  With radiotherapy contraindication;

          -  Pregnant woman or sucking period;

          -  With repture tumor;

          -  With other cancer in previous five years;

          -  With chemothrapy, target therapy or immunosuppressive drugs therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei-Zhong Tang, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cancer Hospital of Guangxi Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Hepatobilliary Surgery, Affiliated Tumor of Guangxi University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Yoon SM, Ryoo BY, Lee SJ, Kim JH, Shin JH, An JH, Lee HC, Lim YS. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial. JAMA Oncol. 2018 May 1;4(5):661-669. doi: 10.1001/jamaoncol.2017.5847.</citation>
    <PMID>29543938</PMID>
  </reference>
  <reference>
    <citation>He M, Li Q, Zou R, Shen J, Fang W, Tan G, Zhou Y, Wu X, Xu L, Wei W, Le Y, Zhou Z, Zhao M, Guo Y, Guo R, Chen M, Shi M. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial. JAMA Oncol. 2019 Jul 1;5(7):953-960. doi: 10.1001/jamaoncol.2019.0250.</citation>
    <PMID>31070690</PMID>
  </reference>
  <reference>
    <citation>Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Akazawa K, Yoshimura KI, Johnson P, Arai Y; SILIUS study group. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. Lancet Gastroenterol Hepatol. 2018 Jun;3(6):424-432. doi: 10.1016/S2468-1253(18)30078-5. Epub 2018 Apr 7.</citation>
    <PMID>29631810</PMID>
  </reference>
  <reference>
    <citation>Li N, Feng S, Xue J, Wei XB, Shi J, Guo WX, Lau WY, Wu MC, Cheng SQ, Meng Y. Hepatocellular carcinoma with main portal vein tumor thrombus: a comparative study comparing hepatectomy with or without neoadjuvant radiotherapy. HPB (Oxford). 2016 Jun;18(6):549-56. doi: 10.1016/j.hpb.2016.04.003. Epub 2016 May 7.</citation>
    <PMID>27317960</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 17, 2019</study_first_submitted>
  <study_first_submitted_qc>July 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2019</study_first_posted>
  <last_update_submitted>September 1, 2019</last_update_submitted>
  <last_update_submitted_qc>September 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangxi Medical University</investigator_affiliation>
    <investigator_full_name>Jian-Hong Zhong</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

